These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7957802)

  • 1. Pattern of iron excretion in relation to haemoglobin level and iron load in 8 haematological patients following the administration of subcutaneous deferrioxamine.
    Di Palma A; Moratelli S; Tolomelli P; Giuberti M; Tenan R; Fagioli F; Landi L; Toffoli C; Atti G; Vullo C
    Eur J Haematol; 1994 Oct; 53(4):197-200. PubMed ID: 7957802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined oral and parenteral iron chelation in beta thalassaemia major.
    Balveer K; Pyar K; Wonke B
    Med J Malaysia; 2000 Dec; 55(4):493-7. PubMed ID: 11221163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload.
    Hussain MA; Green N; Flynn DM; Hussein S; Hoffbrand AV
    Lancet; 1976 Dec; 2(7998):1278-80. PubMed ID: 63749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
    Silvestroni E; Bianco I; Graziani B; Lerone M; Valente M; Congedo P; Ponzini D; Costantini S
    Acta Haematol; 1982; 68(2):115-23. PubMed ID: 6812366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA; Taqi A; Deghaidi A
    Pediatr Hematol Oncol; 2004; 21(5):453-60. PubMed ID: 15205089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone.
    Alymara V; Bourantas D; Chaidos A; Bouranta P; Gouva M; Vassou A; Tzouvara E; Bourantas KL
    Hematol J; 2004; 5(6):475-9. PubMed ID: 15570288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-thalassaemia--the Johannesburg experience.
    Poole JE; Cohn RJ; Roode H; Spector I
    S Afr Med J; 1989 Apr; 75(8):367-70. PubMed ID: 2652340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine.
    Olivieri NF; Berriman AM; Tyler BJ; Davis SA; Francombe WH; Liu PP
    Am J Hematol; 1992 Sep; 41(1):61-3. PubMed ID: 1503101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excretion of iron in response to deferoxamine in sickle cell anemia.
    Cohen A; Schwartz E
    J Pediatr; 1978 Apr; 92(4):659-62. PubMed ID: 633013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major.
    Richardson ME; Matthews RN; Alison JF; Menahem S; Mitvalsky J; Byrt E; Harper RW
    Aust N Z J Med; 1993 Dec; 23(6):656-61. PubMed ID: 8141693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.
    Aydinok Y; Ulger Z; Nart D; Terzi A; Cetiner N; Ellis G; Zimmermann A; Manz C
    Haematologica; 2007 Dec; 92(12):1599-606. PubMed ID: 18055982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
    Waheed N; Ali S; Butt MA
    J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.
    Abdelrazik N
    Hematology; 2007 Dec; 12(6):577-85. PubMed ID: 17852442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of iron overload due to repeated transfusions with subcutaneous infusions of desferrioxamine (author's transl)].
    Girot R; Thévenin M; Bouveret JP; Jeannel F; Rymer JC
    Arch Fr Pediatr; 1980 Apr; 37(4):241-7. PubMed ID: 7406638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ; Göbel U; Christaras A; Janssen G
    Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An alternative to continuous subcutaneous infusion of desferrioxamine in thalassaemic patients.
    Di Gregorio F; Romeo MA; Pizzarelli G; Aiello G; Russo G
    Br J Haematol; 1997 Sep; 98(3):601-2. PubMed ID: 9332314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
    Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
    Kolnagou A; Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Res (Stuttg); 2017 Jul; 67(7):404-411. PubMed ID: 28320041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.
    Kolnagou A; Kleanthous M; Kontoghiorghes GJ
    Hemoglobin; 2011; 35(3):186-98. PubMed ID: 21599431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.